GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » YoY Rev. per Sh. Growth

Nektar Therapeutics (LTS:0UNL) YoY Rev. per Sh. Growth : -2.63% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Nektar Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 was -2.63%.

Nektar Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was $0.11.


Nektar Therapeutics YoY Rev. per Sh. Growth Historical Data

The historical data trend for Nektar Therapeutics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics YoY Rev. per Sh. Growth Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.11 30.69 -35.05 -11.51 -3.66

Nektar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.93 -6.90 0.79 6.84 -2.63

Nektar Therapeutics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Nektar Therapeutics's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.474-0.492)/ | 0.492 |
=-3.66 %

Nektar Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2024 )
=(Revenue per Share (Q: Mar. 2024 )-Revenue per Share (Q: Mar. 2023 )) / | Revenue per Share (Q: Mar. 2023 )) |
=(0.111-0.114)/ | 0.114 |
=-2.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nektar Therapeutics YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (LTS:0UNL) Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (LTS:0UNL) Headlines

No Headlines